UBS Group AG Ceases to Be Substantial Holder in Artrya Limited on 4 November 2026

Mukul

06 November 2026 04:04 PM AEDT

UBS Group AG Ceases to Be Substantial Holder in Artrya Limited on 4 November 2026

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Artrya Limited (ASX:AYA) has received formal notification that UBS Group AG and its related bodies corporate ceased to be a substantial holder in the company on 4 November 2026, according to a Form 605 filing lodged with the exchange.

Key Points

UBS Group AG and its related bodies corporate ceased to be a substantial holder in Artrya Limited on 4 November 2026.
The previous substantial holder notice was given to the company on 27 October 2026 and was dated 23 October 2026.
Changes in relevant interests were carried out by UBS Securities Australia Ltd through a series of buy and sell transactions in ordinary shares on 26 and 27 October 2026.
UBS Securities LLC also recorded a stock borrowing transaction of 172,000 ordinary shares on 26 October 2026.
The notice was signed by Ruby Ko, authorised signatory, on 6 November 2026.

Cessation of Substantial Holding in Artrya Limited

According to the filing, UBS Group AG and its related bodies corporate formally ceased to hold a substantial interest in Artrya Limited (ACN 624 005 741) on 4 November 2026. The notification was made via a Form 605 under Section 671B of the Corporations Law. The previous substantial holding notice had been provided to the company on 27 October 2026, with that notice dated 23 October 2026. No changes in association were reported, and no persons were identified as having become or ceased to be associates of UBS Group AG in connection with this filing.

Share Transactions on 26 and 27 October 2026

Appendix A of the filing details a series of changes in relevant interests conducted by UBS Securities Australia Ltd across 26 and 27 October 2026, involving multiple buy and sell transactions in Artrya ordinary shares. On 26 October 2026, sell transactions included parcels ranging from 140 to 164,879 ordinary shares, while buy transactions on the same date included parcels ranging from 85 to 160,235 ordinary shares. On 27 October 2026, further sell transactions were recorded, including parcels of 13,631, 89,967 and 116,141 ordinary shares, alongside additional buy transactions. UBS Securities LLC separately recorded a stock borrowing of 172,000 ordinary shares on 26 October 2026, with no consideration disclosed for that transaction.

Authorisation and Filing Details

The Form 605 notice was signed by Ruby Ko in the capacity of authorised signatory on behalf of UBS Group AG, with the signing date recorded as 6 November 2026. The filing identifies Ruby Ko as a member of Group Compliance, Operational Risk Control. No changes in association were declared within the notice, and no additional addresses for named persons were provided. The filing covers ordinary shares in Artrya Limited and relates solely to the cessation of UBS Group AG's substantial holding status as defined under the Corporations Law.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.